Anti-epidermal growth factor receptor (EGFR) treatment has been successfully applied in clinical cancer therapy. However, the clinical efficacy of first-generation reversible EGFR inhibitors, such as gefitinib and erlotinib, is limited by the development of drug-resistant mutations, including the gatekeeper T790M mutation and upregulation of alternative signaling pathways. Second-generation irreversible EGFR inhibitors that were designed to overcome the drug resistance due to the T790M mutation have thus far had limited success. Here we report a novel reversible EGFR inhibitor, SKLB1206, which has potent activity against EGFR with gefitinib-sensitive and resistant (T790M) mutations. In addition, SKLB1206 has also considerable inhibition potency against some other related onco-kinases, including ErbB2, ErbB4 and vascular endothelial growth factor receptor 2 (VEGFR2).
Introduction
Mutations or overexpression of epidermal growth factor receptor (EGFR) have been associated with a variety of human malignancies, including lung, colorectal, prostate, head and neck cancers (1) (2) (3) . The EGFR kinase has thus been thought as an important drug target for treating these types of cancers. Currently, numerous small molecular EGFR inhibitors have also been reported, of which the most successful examples are gefitinib (Iressa) and erlotinib (Tarceva), which have been approved for clinically treating non-small cell lung cancer (NSCLC) (4) (5) (6) . Gefitinib Approximately half of cases are a single secondary mutation in EGFR exon 20 that leads to T790M substitutions (7) (8) (9) . The limited response rate (primary resistance) and acquired resistance (secondary resistance) constitute the main challenges in current anti-cancer therapy targeting EGFR.
Several strategies could be used to conquer the current drug resistance to EGFR inhibitors, including directly acting on EGFR T790M mutation, concomitant inhibition of EGFR and other related receptor tyrosine kinases (RTKs), and simultaneous interference of angiogenesis (10- to decreased binding velocity to the mutant kinase (17) . In this respect, reversible inhibitors would be more superior or at least another better option compared with irreversible counterparts. Secondly concomitant inhibition of other RTKs that are tightly associated with EGFR has been demonstrated to be helpful for overcoming the drug resistance, for example, the other ErbB family members. Numerous studies have indicated that interactions between ErbB family members play an important role in human malignancies (18) (19) (20) . Preclinical experiments have shown that ErbB receptors act synergistically to transform NIH3T3 cells (21, 22) , and some human cancers that overexpress both EGFR and ErbB2 have a poorer prognosis than cancers that overexpress either receptor alone (23, 24) . Therefore, it is expected that simultaneous inhibition of other ErbB family members in addition to EGFR may lead to the enhancement of therapeutic efficacy of EGFR inhibitors and reduce the drug resistance. Thirdly, additional antiangiogenesis activity would help to accentuate the antitumor effects of EGFR inhibitors since angiogenesis plays important roles in the sustained growth and metastasis of tumors through providing nutrients and oxygen to tumor tissues (25 6 and neck and colon cancers, including decreased tumor vascularity and increased tumor and endothelial cell apoptosis compared with sole inhibition of EGFR (26) (27) (28) .
Ideally, simultaneous use of these strategies is expected to be able to provide improved and/or broader spectrum anti-cancer efficacy versus selective EGFR inhibitors and better overcome the drug resistance.
Here we report a novel reversible EGFR inhibitor, named SKLB1206 that is a purine derivative, which was obtained by utilizing the technology of computer aided drug discovery (CADD) and lead optimization (related investigations will be reported elsewhere). SKLB1206 exhibits high inhibition potency against EGFR with gefitinib-sensitive or -resistance (T790M) mutations. In addition, SKLB1206 has also considerable inhibition activity against some other related onco-kinases, including ErbB2, ErbB4 and VEGFR2. SKLB1206 displayed potent antitumor effect both in vitro and in vivo and excellent oral bioavailability which provided a solid base for further clinical development of SKLB1206. 
Materials and Methods

Cell culture and regents
Cell lines were acquired from the American Type Culture Collection except specifically mentioned. All the cell lines were maintained in the designated medium (Supplementary Table S1 ) supplemented with 10% FBS (Gibco) and passaged for less than 6 months after receipt or resuscitation. No further authentication was done for tumor cell lines. Recombinant human EGF was purchased from Prospec Company.
Recombinant human VEGF 165 and bFGF were obtained from PeproTech Company.
SKLB1206 was synthesized at the State Key Laboratory of Biotherapy, Sichuan University. Gefitinib, Sunitinib, and BIBW2992 were obtained from commercial sources. For all in vitro assays and zebrafish studies, a 10 mM stock solution of each compound was prepared in DMSO and diluted in optimal assay buffers or culture medium.
Kinase inhibition assay
The IC 50 values of SKLB1206 for kinase inhibition in vitro were measured by the use of radiometric assays performed by Kinase Profiler service provided by Millipore as described in detail in the Supplementary Methods.
Cell proliferation assay
Cell proliferation assay was performed as previously described (29) . The IC 50 values were calculated by GraphPad Prism 5.01 software. 
Colony formation assay
Western blot analysis
Cells lysates were subjected to SDS-PAGE and then transferred to PVDF membranes (Millipore). All antibodies were purchased from Cell Signaling Technology. Specific proteins were detected using by the enhanced chemiluminescence system (Millipore).
Growth factor-mediated endothelial cell proliferation assay
The endothelial cell proliferation assay was carried out as previously described (30) .
In vitro capillary-like tube formation assay
The tube formation assay was performed as described previously (31) .
Migration assay
Migration assay was done following the method reported previously (32) and is described in detail in Supplementary Methods.
Transwell invasion assay
The cell invasion assay was performed as described previously (33) with some modifications and is described in detail in Supplementary Methods.
In vivo live fluorescent zebrafish assay
The transgenic zebrafish (FLK-1:EGFP) embryos were grown and maintained according to the protocols described in ref (34) . 
Pharmacokinetic assessments
Blood from SD rats dosed with SKLB1206 was collected in EDTA-containing tubes and the plasma was isolated by the centrifugation. Plasma concentrations of SKLB1206 were determined by liquid chromatography tandem mass spectrometry (LC/MS).
Alginate-encapsulate tumor cell assay
The alginate-encapsulate tumor cell assay was performed as described previously 
TUNEL detection
The analysis of apoptotic cells in the tumor tissue was performed by TUNEL staining using an apoptotic cell detection kit (Roche). Images of the sections were taken by a fluorescence microscope. The Apoptosis index was calculated by dividing the number of TUNEL-positive cells by the total number of cells in the field.
Immunohistochemistry
Paraffin-embedded sections of tumors were stained with Hematoxylin and esosin using standard methods. Immunohistochemical staining was performed using antibodies from Cell Signaling Technology. CD31 (BD Bioscience) staining was performed using frozen sections of tissue embedded in OCT (36) .
Statistical analysis
SPSS 11.5 was used for statistical analysis. The statistical significance of results in all of the experiments was determined by Student's t test and ANOVA. P value < 0.05 was considered statistically significant.
Results
The kinase inhibition profile of SKLB1206 against recombinant human protein kinases
The structure of SKLB1206 and gefitinib is displayed in Fig. 1A and the kinase inhibition profile of SKLB1206 against a panel of kinases is shown in Supplementary respectively. This compound also inhibited ErbB2, ErbB4, and VEGFR2 with moderate activity (IC 50 s: 0.9 μM, 0.3 μM, and 0.03 μM, respectively), but only weakly inhibited AXL, EPHB4, FLT3, and MERTK (IC 50 s: 1.5 μM, 2.4 μM, 2.7 μM, and 2.5 μM, respectively). SKLB1026 displayed almost no inhibition activity to other 44 selected protein kinases. All of these demonstrate that SKLB1206 is a potent EGFR (both activating and drug-resistance mutations) inhibitor with good kinase spectrum selectivity.
Inhibitions of tumor cell growth and colony formation in vitro
The anti-viability activity of SKLB1206 against various tumor cell lines was measured using MTT method (Table 1 and Supplementary Fig. S1 ). SKLB1206 MDA-MB-231, SW480, and HCT116 were resistant to both SKLB1206 and gefitinib (IC 50 > 1 μM). Similarly, in MCF-7 cell line containing PI3K mutation and HepG2 cell line overexpressing Aurora B, both SKLB1206 and gefitinib displayed minimal growth inhibitory effect (IC 50 > 4 μM). These data exclude the possibility that the anti-viability activity of SKLB1206 is due to its cell toxicity. Collectively, these results clearly indicate that SKLB1206 has improved antitumor potency to a broader spectrum of tumor cells compared with gefitinib.
Colony formation assay was further performed to visually assess the anti-viability activity of SKLB1206. 
Inhibition of ErbB receptor autophosphorylation and inactivation of downstream signaling proteins in cell cultures
The ability of SKLB1206 to inhibit the activation of EGFR, ErbB-2, and downstream signaling proteins in intact cells was assessed by Western blot analysis.
In gefitinib-sensitive HCC827 cell line, SKLB1206 inhibited EGFR phosphorylation at lower concentrations of drug with an estimated IC 50 value of 0.003 μM compared with gefitinib with an estimated IC 50 value of 0.01 μM ( Fig. 2A) . This was accompanied by corresponding inhibition of the downstream targets, AKT and ERK. To assess the effect of SKLB1206 on the phosphorylation of ErbB2, a classical ErbB2-overexpressing cell line, BT474, was used. SKLB1206 displayed good inhibition potency against the ErbB2 phosphorylation with an estimated IC 50 value of 1 μM, still superior to gefitinib (Fig. 2C) .
Anti-angiogenesis effect of SKLB1206
To evaluate the anti-angiogenesis effect of SKLB1206, the anti-proliferative ability of SKLB1206 against human umbilical vein endothelial cell (HUVEC) was first assessed by MTT assay. SKLB1206 showed a good anti-proliferative activity against VEGF and EGF-stimulated HUVEC with IC 50 values of 0.102 μM and 0.310 μM, respectively ( Supplementary Fig. S2A ). Then the inhibitory efficacy of SKLB1206 to HUVEC migration, invasion, and tube formation, which are indispensable for angiogenesis, was examined. In wound-healing assay, we found that SKLB1206 significantly inhibited the migration of HUVECs in a dose-dependent manner and the migration ability of HUVEC was inhibited by about 70% in the presence of 1.25 μM of SKLB1206 (Fig. 3A and Supplementary Fig. S2B ). In addition, in the transwell assay assessing the invasion ability of HUVECs, 1 μM of SKLB1206 inhibited almost all invasion activities of HUVECs (Fig. 3A and Supplementary Fig. S2B ). 
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formation of HUVECs by 50% and 2.5 μM potently blocked the tube formation of HUVECs ( Fig. 3A and Supplementary Fig. S2B ). Taken together, these data indicate that SKLB1206 can inhibit angiogenesis in vitro.
In order to test the anti-angiogenesis ability of SKLB1206 in vivo, we examined the effect of SKLB1206 on embryonic angiogenesis in zebrafish. Treatment of live fish embryos with SKLB1206 completely blocked the formation of intersegmental vessel at the concentration of 5 μM while preserving fluorescence in the doral aorta and major cranial vessels, and 2.5 μM of sunitinib showed the similar effect (Fig. 3B ).
In the presence of 1.25 μM or 2.5 μM of SKLB1206, the formation of intersegmental vessel was significantly inhibited compared with vehicle control group, exhibiting a dose-dependent inhibition pattern.
Finally, to mimic better the process of angiogenesis induced by tumor cells in vivo and determine the inhibitory effect of SKLB1206 on it, we performed an alginate-encapsulate tumor cell assay. In SKLB1206-treated mice, new blood vessels in alginate beads were apparently reduced and FITC-dextran uptake was significantly decreased when compared with control group (Fig. 3C) . Collectively, based on the above results, we can conclude that SKLB1206 efficiently inhibited angiogenesis both in vitro and in vivo.
Antitumor efficacy of SKLB1206 in relevant human tumor xenograft models
A total of six relevant human tumor xenograft models were used, including two gefitinib-sensitive NSCLC HCC827 and PC-9 tumor models bearing EGFR activating mutation, one gefitinib-resistant NSCLC H1975 tumor model harboring T790M 
mutation in EGFR, one wild-type EGFR-overexpressing A431 epidermoid carcinoma xenograft model, one wild-type EGFR-driven LoVo colon carcinoma xenograft model, and one ErbB2-overexpressing N87 gastric carcinoma xenograft model.
In the HCC827 tumor model, SKLB1206 at all dose levels markedly induced tumor regression and 20 mg/kg of SKLB1206 displayed complete tumor regression in all treated mice within a week as effectively as gefitinib did at the dose of 100 mg/kg (Fig. 4 and Supplementary Fig. S3A ). Even 2 mg/kg of SKLB1206 resulted in almost complete tumor regression at the end of treatment (Fig. 4) . In another EGFR activating mutation tumor, PC-9 xenograft model, SKLB1206 also significantly induced tumor regression at the indicated doses even with a low dose of 5 mg/kg ( Table S3 ). However, treatment with gefitinib even at 100 mg/kg only produced a marginal effect on tumor growth (23% inhibition). These results show that SKLB1206 is, to a great extent, capable of overcoming the acquired drug-resistance of gefitinib. Furthermore, because SKLB1206 was also active against WT EGFR (Fig. 4 and Supplementary Fig. S3A) . Additionally, the anti-tumor efficacy of SKLB1206 was further studied in LoVo tumor model, which has been recognized as a WT EGFR-driven model showing high basal EGFR phosphorylation (37, 38) . SKLB1206 suppressed tumor growth when administrated to animals between 12.5 mg/kg (89% inhibition, day 21) and 50 mg/kg (105% inhibition, day 21) (Fig. 4) . Finally, growth of the N87 gastric tumor, in which ErbB2 gene is amplified and overexpressed, was completely inhibited by SKLB1206 at doses of 25 mg/kg or higher (Fig. 4) , suggesting that SKLB1206 was also active against ErbB2-overexpressing tumor xenograft model. All antitumor data generated from these six models are summarized in Supplementary Table S3 . In all of the above tumor models, only minor weight loss was associated with the high dose (50 mg/kg) group for SKLB1206, which recovered with continued treatment. However, no significant weight loss was observed in other treatment groups compared with the control group.
Mechanism of action of SKLB1206 in human tumor xenograft models
To determine whether the observed activity in vivo is targeted specifically, immunohistochemistry was first done using tumor tissues isolated from HCC827 tumor model with EGFR activating mutation. In the HCC827 tumor model, we observed a significant decrease in the phosphorylation of EGFR isolated from SKLB1206-treated animals when compared with the control group (Fig. 5A) . A significant reduction in the phosphorylation of AKT and ERK was also observed in the treatment group (Fig. 5A) , indicating that EGFR-mediated downstream signaling pathway was potently inhibited by SKLB1206 in vivo. These tumors exhibited reduced staining of Ki67, implying a significant reduction in proliferating cells in the tumor, and showed more TUNEL-positive cells with dark green fluorescent staining, indicating a significant increased apoptosis in the treatment group when compared with the control group ( Fig. 5A and 5B).
To understand better the mechanism of SKLB1206-mediated antitumor efficacy in different tumor models, we also performed immunohistochemistry analysis in WT EGFR A431 tumor model. As depicted in Fig. 5C , SKLB1206 showed significant inhibition of EGFR and ErbB2 phosphorylation compared with the control group. A significant decrease in Ki67 expression was also observed in SKLB1206-treated group (Fig. 5C ). In addition, the increased apoptosis observed in SKLB1206-treated groups compared with the control group was dose-dependent, with nearly 50% apoptotic index for the dose of 50 mg/kg ( Supplementary Fig. S3B and S3C ). compared with the control group ( Fig. 5D and Supplementary Fig. S3D ), suggesting that the antitumor activity of SKLB1206 in A431 model should be, at least to some extent, attributed to its inhibition of angiogenesis. Taken together, these results clearly demonstrate that SKLB1206 inhibits specific molecular targets in vivo to block proliferation, induce apoptosis and inhibit tumor angiogenesis in human tumor xenograft model.
Pharmacokinetic characteristics of SKLB1206
To account better for the antitumor activity observed in the human tumor xenograft models, pharmacokinetic parameters of SKLB1206 following IV and PO administration to male rats were measured, which results are summarized in Supplementary Table S4 . The plasma concentration versus time profile of SKLB1206 is shown in Supplementary Fig. S4 . After IV at the dose of 20 mg/kg, SKLB1206 displayed a clearance of 38.7 mL/min/kg, with a T 1/2 of 5.7 h. The Vss (18.4 L/kg) was much larger than the volume of total body water (0.67 L/kg), suggesting extravascular distribution. Following oral administration at a single dose of 60 mg/kg, the absorption of SKLB1206 was relatively quick, which reach the maximum concentration in the plasma (C max , 1.05 μg/ml) at 2-6 h. The absolute oral bioavailability of SKLB1206 was 50.1% after an oral dose of 60 mg/kg. 
benefits of EGFR inhibitors gefitinib and erlotinib in clinical practice, most, if not all, patients ultimately develop acquired resistance to these agents (7, 39) . The gatekeeper T790M mutation in EGFR, like the analogous T315I mutation in ABL, is one of the most difficult drug-resistant mutations to overcome at present (40) (41) (42) . In recent years, irreversible EGFR inhibitors have been suggested to combat this type of drug-resistance; the irreversible EGFR inhibitors carry a Michael acceptor functional group and irreversibly alkylate a cysteine (C797) in the ATP binding site of EGFR.
However, most of the quinazoline-based irreversible inhibitors have thus far achieved limited success, which may be related to their inherent weaknesses including relatively large toxicity and decreased binding velocity to the mutant kinase (17) .
SKLB1206 reported here is a reversible EGFR inhibitor. SKLB1206 not only targets the EGFR-activating mutations, but also inhibits efficiently EGFR T790M mutation with IC 50 = 0.046 μM. In addition, SKLB1206 also inhibits other related protein kinases, including ErbB2 (IC 50 : 0.9 μM), ErbB4 (IC 50 : 0.3 μM), and VEGFR2 (IC 50 : 0.03 μM). This multiple target inhibition is expected to be able to lead to the enhancement of the efficacy of SKLB1206 through additive and/or synergistic effect.
And it also could help to overcome the drug-resistance. In the cell line-based assay, SKLB1206 indeed displayed much higher proliferative inhibition potency to HCC827 and PC-9 than gefitinib, although enzymatic inhibition potency of SKLB1206 is comparable with that of gefitinib. The proliferative inhibition to cell lines harboring T790M mutation (H1975 and H820), and overexpressing ErbB2 (BT474), suggests that SKLB1206 has an ability to overcome the drug-resistance (both acquired and de 
novo).
Anti-angiogenesis is another promising approach to anti-cancer therapy (25) .
Angiogenesis is a complex process including endothelial cell proliferation, migration, invasion, and tube formation (43). VEGFR2 is a major mediator of angiogenesis through VEGF-induced signaling in endothelial cell (44) . As SKLB1206 is also a potent inhibitor of VEGFR2 tyrosine kinase, we evaluated the effect of SKLB1206 on anti-angiogenesis by using various methods, including inhibition assays of proliferation, migration, invasion, and tube formation of HUVEC, as well as a zebrafish embryonic angiogenesis assay and an alginate-encapsulate tumor cell assay.
All of these assays validated the anti-angiogenesis effect of SKLB1206.
Clinical studies have shown that sole use of drugs that directly target tumor cells might lead to acquired drug-resistance with a relatively large possibility (7, 39, 45) .
On the other hand, recent investigations have also indicated that sole anti-angiogenesis treatment could have an unintended effect of promoting tumor metastasis (46, 47) . Nevertheless, combined anti-angiogenesis treatment with drugs directly attacking cancer cells might lead to beneficial clinical effects, which has been demonstrated by numerous investigations (26, 27, 29) . SKLB1206 is such a compound with combined pan-ErbB/VEGF receptor inhibitory activities in the same molecule, implying improved antitumor efficacy and broadened application possibilities just like ZD6474 evaluated in xenograft models of EGFR inhibitor resistance (29) . 
